Glycoprotein B Antibodies Completely Neutralize EBV Infection of B Cells
Open Access
- 27 May 2022
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 920467
Abstract
The Epstein–Barr virus (EBV) is the first reported oncogenic herpesvirus that establishes persistent infection in B lymphocytes in 95% of adults worldwide. Glycoprotein B (gB) plays a predominant role in the fusion of the viral envelope with the host cell membrane. Hence, it is of great significance to isolate gB-specific fusion-inhibiting neutralizing antibodies (NAbs). AMMO5 is the only gB NAb but fails to antagonize B-cell infection. It is essential to isolate potent NAbs that can completely block EBV infection of B cells. Using hybridoma technology and neutralization assay, we isolate two gB NAbs 8A9 and 8C12 that are capable of completely neutralizing B-cell infection in vitro. In addition, 8A9 shows cross-reactivity with rhesus lymphocryptovirus (rhLCV) gB. Competitive binding experiments demonstrate that 8A9 and 8C12 recognize novel epitopes that are different from the AMMO5 epitope. The epitopes of 8A9 and 8C12 are mapped to gB D-II, and the AMMO5 epitope is located precisely at gB aa 410–419. We find that 8A9 and 8C12 significantly inhibit gB-derived membrane fusion using a virus-free fusion assay. In summary, this study identifies two gB-specific NAbs that potently block EBV infection of B cells. Our work highlights the importance of gB D-II as a predominant neutralizing epitope, and aids in the rational design of therapeutics or vaccines based on gB.Keywords
Funding Information
- National Natural Science Foundation of China (82073756)
This publication has 75 references indexed in Scilit:
- Fusion of Epstein-Barr Virus with Epithelial Cells Can Be Triggered by αvβ5 in Addition to αvβ6 and αvβ8, and Integrin Binding Triggers a Conformational Change in Glycoproteins gHgLJournal of Virology, 2011
- Epstein-Barr Virus: An Important Vaccine Target for Cancer PreventionScience Translational Medicine, 2011
- Soluble Rhesus Lymphocryptovirus gp350 Protects against Infection and Reduces Viral Loads in Animals that Become Infected with Virus after ChallengePLOS Pathogens, 2011
- Fusing structure and function: a structural view of the herpesvirus entry machineryNature Reviews Microbiology, 2011
- Human antibody titers to Epstein–Barr Virus (EBV) gp350 correlate with neutralization of infectivity better than antibody titers to EBV gp42 using a rapid flow cytometry-based EBV neutralization assayVirology, 2009
- EBV BMRF-2 facilitates cell-to-cell spread of virus within polarized oral epithelial cellsVirology, 2009
- Structure of a trimeric variant of the Epstein–Barr virus glycoprotein BProceedings of the National Academy of Sciences, 2009
- Analysis of Epstein-Barr Virus Glycoprotein B Functional Domains via Linker Insertion MutagenesisJournal of Virology, 2009
- Characterization of EBV gB indicates properties of both class I and class II viral fusion proteinsVirology, 2007
- Antigenic and Mutational Analyses of Herpes Simplex Virus Glycoprotein B Reveal Four Functional RegionsJournal of Virology, 2007